Key result
Updated 2005 ESC guidelines revise recommendations on five pharmacological strategies for chronic heart failure.
Why the study?
Chronic heart failure is associated with high mortality and morbidity, and patients are often misdiagnosed or underprescribed effective medications, necessitating updated evidence-based guidance.
Population
Patients with chronic heart failure
Comparison
Pharmacological strategies including ACE inhibitors, beta-blockers, diuretics, aldosterone antagonists, and angiotensin-II type-1 receptor blockers
Design
Review of updated ESC guidelines incorporating recent large-scale randomized placebo-controlled trials
Authors
Loading...
Guidelines may curb misdiagnosis and underprescribing in CHF; leaves open optimal implementation strategies.
This review summarizes the 2005 ESC guidelines for the pharmacological management of chronic heart failure, highlighting updates from the 2001 guidelines based on new large-scale clinical trial data.
Aldo Pietro Maggioni (2005) conducted a review in Chronic heart failure (CHF). Pharmacological strategies (ACE-inhibitors, beta-blockers, diuretics, aldosterone antagonists, and ARBs) was evaluated. The 2005 ESC guidelines for chronic heart failure incorporate new data from large-scale trials to update recommendations on five pharmacological strategies compared to the 2001 guidance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: